HCPCS J9393: Fulvestrant (Teva) 25 mg injection, not therapeutically equivalent to J9395
HCPCS Level II code J9393 describes a 25 mg injection of fulvestrant (Teva), specified as not therapeutically equivalent to J9395, used as a systemic endocrine anticancer agent; service type is drug administration via injection and the typical site of service is an outpatient infusion or oncology clinic where parenteral antineoplastic therapies are given.
For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.
Customize your policy alerts
Sign up for hcpcs J9393 policy alerts
Get alerted when payer policies referencing J9393 are released or updated.
Monitor payer policy activity